Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Melanoma 117Carcinoma, Non-Small-Cell Lung 102Carcinoma, Renal Cell 69Colorectal Neoplasms 46Neoplasm Metastasis 41Squamous Cell Carcinoma of Head and Neck 39Carcinoma, Hepatocellular 38Neoplasms 36Lung Neoplasms 34Stomach Neoplasms 33Urinary Bladder Neoplasms 22Carcinoma, Transitional Cell 21Hodgkin Disease 20Brain Neoplasms 20Pancreatic Neoplasms 18Ovarian Neoplasms 18Prostatic Neoplasms 17Head and Neck Neoplasms 16Colonic Neoplasms 16Skin Neoplasms 15Triple Negative Breast Neoplasms 14Sarcoma 14Glioblastoma 14Adenocarcinoma Of Esophagus 14Carcinoma, Merkel Cell 13Small Cell Lung Carcinoma 12Rectal Neoplasms 12Esophageal Neoplasms 12Breast Neoplasms 12Uveal Melanoma 11

Interventions

varlilumab 1Vincristine 1Tomography, X-Ray Computed 1Rituximab 1Prednisone 1Nivolumab 1Interferons 1Immunoglobulin G 1Etoposide 1Echocardiography 1EPOCH protocol 1Doxorubicin 1Disulfides 1Cyclophosphamide 1Caves 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphomatoid Granulomatosis × Nivolumab × 1 year × Clear all
NCT03038672 2026-05-12

Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas

National Cancer Institute (NCI)

Phase 2 Active not recruiting
54 enrolled 12 charts
Lymphoid

Plasmablastic Lymphoma, Burkitt Lymphoma, Lymphomatoid Granulomatosis, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Primary Effusion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡